drugset
drugset / Trial / NCT06988956

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

NCT06988956 ↗

Phase 2 Recruiting 95 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.

Timeline

Start
2024-03-31
Primary completion
2027-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg Intravenous
Background S-1 Small molecule 40 mg Oral
Background S-1 Small molecule 50 mg Oral
Background S-1 Small molecule 60 mg Oral
Background S-1 Small molecule 60 mg/m2 Oral

Indications

esophageal squamous cell carcinoma